波士顿的Alloplex引入SUPLEXA, 一种个性化癌症治疗, 第二阶段试验定于2025年进行。 Boston's Alloplex introduces SUPLEXA, a personalized cancer treatment, with Phase 2 trials set for 2025.

波士顿的Alloplex生物治疗 引进了SUPLEXA, 这是一种个性化的癌症治疗, 增强病人的免疫细胞 以对抗癌症。 Boston's Alloplex Biotherapeutics has introduced SUPLEXA, a personalized cancer treatment that enhances patients' immune cells to combat cancer. 这一过程涉及隔离免疫细胞,在实验室中恢复免疫细胞,并在一次抽血后恢复免疫细胞。 The process involves isolating immune cells, reactivating them in a lab, and reinfusing them after a single blood draw. 早期结果显示,在先进的直肠和肾细胞癌中,安全性很强,结果积极。 Early results show strong safety and positive outcomes in advanced colorectal and renal cell cancers. 第2阶段试验定于2025年初进行,试验SUPLEXA和免疫检查站抑制剂。 Phase 2 trials are set for early 2025, testing SUPLEXA alongside immune checkpoint inhibitors.